<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>74</volume><submitter>Statlender L</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Vasopressin has become an important vasopressor drug while treating a critically ill patient to maintain adequate mean arterial pressure. Diabetes insipidus (DI) is a rare syndrome characterized by the excretion of a large volume of diluted urine, inappropriate for water homeostasis. We noticed that several COVID19 patients developed excessive polyuria suggestive of DI, with a concomitant plasma sodium-level increase and/or low urine osmolality. We noticed a temporal relationship between vasopressin treatment cessation and polyuria periods. We reviewed those cases to better describe this phenomenon.&lt;h4>Methods&lt;/h4>We retrospectively collected COVID19 ECMO patients' (from July 6, 2020, to November 30, 2021) data from the electronic medical records. By examining urine output,</pubmed_abstract><journal>Journal of critical care</journal><pagination>154211</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9828890</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Transient diabetes insipidus in critically ill COVID19 patients.</pubmed_title><pmcid>PMC9828890</pmcid><pubmed_authors>Singer P</pubmed_authors><pubmed_authors>Statlender L</pubmed_authors><pubmed_authors>Kagan I</pubmed_authors><pubmed_authors>Bendavid I</pubmed_authors><pubmed_authors>Kaptzon S</pubmed_authors><pubmed_authors>Hellerman M</pubmed_authors><pubmed_authors>Fishman G</pubmed_authors><pubmed_authors>Gorfil D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transient diabetes insipidus in critically ill COVID19 patients.</name><description>&lt;h4>Purpose&lt;/h4>Vasopressin has become an important vasopressor drug while treating a critically ill patient to maintain adequate mean arterial pressure. Diabetes insipidus (DI) is a rare syndrome characterized by the excretion of a large volume of diluted urine, inappropriate for water homeostasis. We noticed that several COVID19 patients developed excessive polyuria suggestive of DI, with a concomitant plasma sodium-level increase and/or low urine osmolality. We noticed a temporal relationship between vasopressin treatment cessation and polyuria periods. We reviewed those cases to better describe this phenomenon.&lt;h4>Methods&lt;/h4>We retrospectively collected COVID19 ECMO patients' (from July 6, 2020, to November 30, 2021) data from the electronic medical records. By examining urine output,</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-22T19:57:51.302Z</modification><creation>2025-04-06T02:55:31.337Z</creation></dates><accession>S-EPMC9828890</accession><cross_references><pubmed>36630859</pubmed><doi>10.1016/j.jcrc.2022.154211</doi></cross_references></HashMap>